Stay updated with breaking news from Human Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WALTHAM, Mass., Sept. 27, 2023 -- Xilio Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with...
At the highest dose 4 out of 4 PTCL patients achieved a response using the original manufacturing process Ongoing complete metabolic responses in 2 out of 4 patients at 15 and 18-months post-dosing at... | June 16, 2023
First-in-class Lusvertikimab (OSE-127) is the most advanced anti-IL-7R mAb. Ongoing clinical Phase 2 trial in Ulcerative Colitis sponsored by OSE Immunotherapeutics after positive futility
OSE Immunotherapeutics Updates on Anti-IL-7 Receptor Antagonist OSE-127/S95011, a Breakthrough Approach in Chronic Inflammatory Autoimmune Diseases and Hematology· Positive Phase 1 clinical results published in 'The Journal of Immunology’ (online)· &...
Positive Phase 1 clinical results published in 'The Journal of Immunology' (online) Two ongoing Phase 2 clinical trials in Ulcerative Colitis and primary Sjögren's Syndrome Positive